ClinicalTrials.gg
CompletedNCT07685600Updated Nov 3, 2026

Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants

A Phase 1 interventional study of AZD4144 and AZD4144 in Healthy, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to assess the pharmacokinetics (PK) of AZD4144 when administered alone and in combination with itraconazole in healthy participants.

Read the detailed description

This is an open-label, randomised, two arm, 3 period, fixed sequence study in healthy participants.

The study will include two parallel, independent arms with one arm evaluating oral administration of AZD4144 and the other evaluating AZD4144 administered as an intravenous (IV) infusion.

Each study arm will comprise of:

  1. A screening period of up to 28 days.
  2. Three treatment periods during which participants will receive AZD4144 alone, itraconazole alone, and AZD4144 in combination with itraconazole.
  3. A final follow-up visit.
02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Cardiorenal diseases
  • Cryopyrin
  • Drug-drug interaction
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and/or female participants with suitable veins for cannulation or repeated venipuncture.
  2. (BMI) between 18.0 and 30.0 kg/m², inclusive, and body weight of at least 50 kg.
  3. Female participants of must have a negative serum or urine pregnancy test and must agree to use highly effective throughout the study and follow-up period.
  4. Male participants must agree to use adequate contraception and refrain from sperm donation during the study and for the protocol-specified period after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Any disease or medical condition that may interfere with study participation or interpretation of results.
  2. History or presence of gastrointestinal, hepatic, renal or any other condition known to interfere absorption, distribution, metabolism, or excretion of study drugs.
  3. Any clinically important illness, medical/surgical procedure, or trauma.
  4. Active systemic bacterial, viral, or fungal infection.
  5. Clinically significant serious active or chronic infections.
  6. Known history of primary immunodeficiency (congenital or acquired) or an underlying condition that predisposes to infection.
  7. Concomitant , treatment.
  8. Clinically significant abnormalities in physical examination, vital signs, 12-lead (ECG), or clinical laboratory assessments.
  9. Known or allergy to AZD4144, itraconazole, or any of the study interventions.
  10. Positive screening test for drugs of abuse, alcohol, virus, virus, or (HIV).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Arm 1: Oral AZD4144

    In Period 1, participants will receive a single oral dose of AZD4144 on Day 1. In Period 2, participants will receive itraconazole alone, administered orally, with twice-daily dosing on Day 7 followed by once-daily dosing on Days 8 and 9. In Period 3, participants will receive a single oral dose of AZD4144 on Day 10 in combination with once-daily oral itraconazole till Day 15.

    Drug: AZD4144 · Drug: Itraconazole

  • Experimental
    Arm 2: IV Infusion AZD4144

    In Period 1, participants will receive a single IV infusion of AZD4144 on Day 1. In Period 2, participants will receive itraconazole alone, administered orally, with twice-daily dosing on Day 7 followed by once-daily dosing on Days 8 and 9. In Period 3, participants will receive a single IV infusion of AZD4144 on Day 10 in combination with once-daily oral itraconazole till Day 15.

    Drug: AZD4144 · Drug: Itraconazole

Interventions

  • AZD4144 will be administered orally.

  • AZD4144 will be administered as an IV infusion.

  • Itraconazole will be administered orally.

06

What researchers measure

Primary outcomes

  1. Area under concentration time curve from time 0 to infinity (AUCinf)

    To assess the effect of itraconazole on the PK (AUCinf) of AZD4144

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  2. Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the effect of itraconazole on the PK (AUClast) of AZD4144

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  3. Maximum observed drug concentration (Cmax)

    To assess the effect of itraconazole on the PK (Cmax) of AZD4144

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

Secondary outcomes

  1. Total body clearance (CL)

    To describe the PK (CL) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  2. Apparent total body clearance (CL/F)

    To describe the PK (CL/F) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  3. Volume of distribution during the terminal phase (Vz)

    To describe the PK (Vz) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  4. Apparent volume of distribution based on the terminal phase (Vz/F)

    To describe the PK (Vz/F) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  5. Terminal elimination half life (t½λz)

    To describe the PK (t½λz) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

  6. Time to reach maximum observed concentration (tmax)

    To describe the PK (tmax) of AZD4144 when administered alone, and in combination with itraconazole

    Time frame: Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Oct 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Jul 30, 2026
Primary completionActual
Oct 22, 2026
CompletionActual
Oct 22, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Oct 29, 2026→Oct 22, 2026 (actual)
moved 2 times, Sep 28, 2026 – Nov 3, 2026
Study completion
Oct 29, 2026→Oct 22, 2026 (actual)
moved 2 times, Sep 28, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Oct 28, 2026→Oct 22, 2026 (now actual)
    Study completion Oct 28, 2026→Oct 22, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details
  2. Sep 28, 2026
    Primary completion Oct 29, 2026→Oct 28, 2026
    Study completion Oct 29, 2026→Oct 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07685600
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jul 30, 2026
Primary completion
Oct 22, 2026
Completion
Oct 22, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berzanoflast

Start the discussion